Patents by Inventor Kenji Kanbe
Kenji Kanbe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140322775Abstract: It is intended to provide a novel NAD+-independent myo-inositol 2-dehydrogenase which converts myo-inositol into scyllo-inosose in the absence of NAD+; a novel enzyme scyllo-inositol dehydrogenase which stereospecifically reduces scyllo-inosose into scyllo-inositol in the presence of NADH or NADPH; and a novel microorganism which belongs to the genus Acetobacter or Burkholderia and can convert myo-inositol into scyllo-inositol. By using these enzymes or the microorganism, scyllo-inositol is produced. Furthermore, scyllo-inositol is purified by adding boric acid and a metal salt to a liquid mixture containing scyllo-inositol and a neutral saccharide other than scyllo-inositol to form a scyllo-inositol/boric acid complex, separating the complex from the liquid mixture, dissolving the thus separated complex in an acid to give an acidic solution or an acidic suspension and then purifying scyllo-inositol from the acidic solution or the acidic suspension.Type: ApplicationFiled: March 25, 2014Publication date: October 30, 2014Applicant: HOKKO CHEMICAL INDUSTRY CO., LTD.Inventors: Masanori Yamaguchi, Yuichi Kita, Tetsuya Mori, Kenji Kanbe, Akihiro Tomoda, Atsushi Takahashi, Wakako Ichikawa
-
Patent number: 8715974Abstract: It is intended to provide a novel NAD+-independent myo-inositol 2-dehydrogenase which converts myo-inositol into scyllo-inosose in the absence of NAD+; a novel enzyme scyllo-inositol dehydrogenase which stereospecifically reduces scyllo-inosose into scyllo-inositol in the presence of NADH or NADPH; and a novel microorganism which belongs to the genus Acetobacter or Burkholderia and can convert myo-inositol into scyllo-inositol. By using these enzymes or the microorganism, scyllo-inositol is produced. Furthermore, scyllo-inositol is purified by adding boric acid and a metal salt to a liquid mixture containing scyllo-inositol and a neutral saccharide other than scyllo-inositol to form a scyllo-inositol/boric acid complex, separating the complex from the liquid mixture, dissolving the thus separated complex in an acid to give an acidic solution or an acidic suspension and then purifying scyllo-inositol from the acidic solution or the acidic suspension.Type: GrantFiled: March 8, 2013Date of Patent: May 6, 2014Assignee: Hokko Chemical Industry Co., Ltd.Inventors: Masanori Yamaguchi, Yuichi Kita, Tetsuya Mori, Kenji Kanbe, Akihiro Tomoda, Atsushi Takahashi, Wakako Ichikawa
-
Publication number: 20130196417Abstract: It is intended to provide a novel NAD+-independent myo-inositol 2-dehydrogenase which converts myo-inositol into scyllo-inosose in the absence of NAD+; a novel enzyme scyllo-inositol dehydrogenase which stereospecifically reduces scyllo-inosose into scyllo-inositol in the presence of NADH or NADPH; and a novel microorganism which belongs to the genus Acetobacter or Burkholderia and can convert myo-inositol into scyllo-inositol. By using these enzymes or the microorganism, scyllo-inositol is produced. Furthermore, scyllo-inositol is purified by adding boric acid and a metal salt to a liquid mixture containing scyllo-inositol and a neutral saccharide other than scyllo-inositol to form a scyllo-inositol/boric acid complex, separating the complex from the liquid mixture, dissolving the thus separated complex in an acid to give an acidic solution or an acidic suspension and then purifying scyllo-inositol from the acidic solution or the acidic suspension.Type: ApplicationFiled: March 8, 2013Publication date: August 1, 2013Applicant: HOKKO CHEMICAL INDUSTRY CO., LTD.Inventors: Masanori Yamaguchi, Yuichi Kita, Tetsuya Mori, Kenji Kanbe, Akihiro Tomoda, Atsushi Takahashi, Wakako Ichikawa
-
Patent number: 8409833Abstract: It is intended to provide a novel NAD+-independent myo-inositol 2-dehydrogenase which converts myo-inositol into scyllo-inosose in the absence of NAD+; a novel enzyme scyllo-inositol dehydrogenase which stereospecifically reduces scyllo-inosose into scyllo-inositol in the presence of NADH or NADPH; and a novel microorganism which belongs to the genus Acetobacter or Burkholderia and can convert myo-inositol into scyllo-inositol. By using these enzymes or the microorganism, scyllo-inositol is produced. Furthermore, scyllo-inositol is purified by adding boric acid and a metal salt to a liquid mixture containing scyllo-inositol and a neutral saccharide other than scyllo-inositol to form a scyllo-inositol/boric acid complex, separating the complex from the liquid mixture, dissolving the thus separated complex in an acid to give an acidic solution or an acidic suspension and then purifying scyllo-inositol from the acidic solution or the acidic suspension.Type: GrantFiled: February 25, 2010Date of Patent: April 2, 2013Assignee: Hokko Chemical Industry Co., Ltd.Inventors: Masanori Yamaguchi, Yuichi Kita, Tetsuya Mori, Kenji Kanbe, Akihiro Tomoda, Atsushi Takahashi, Wakako Ichikawa
-
Publication number: 20100261238Abstract: It is intended to provide a novel NAD+-independent myo-inositol 2-dehydrogenase which converts myo-inositol into scyllo-inosose in the absence of NAD+; a novel enzyme scyllo-inositol dehydrogenase which stereospecifically reduces scyllo-inosose into scyllo-inositol in the presence of NADH or NADPH; and a novel microorganism which belongs to the genus Acetobacter or Burkholderia and can convert myo-inositol into scyllo-inositol. By using these enzymes or the microorganism, scyllo-inositol is produced. Furthermore, scyllo-inositol is purified by adding boric acid and a metal salt to a liquid mixture containing scyllo-inositol and a neutral saccharide other than scyllo-inositol to fonts a scyllo-inositol/boric acid complex, separating the complex from the liquid mixture, dissolving the thus separated complex in an acid to give an acidic solution or an acidic suspension and then purifying scyllo-inositol from the acidic solution or the acidic suspension.Type: ApplicationFiled: February 25, 2010Publication date: October 14, 2010Applicant: HOKKO CHEMICAL INDUSTRY CO., LTD.Inventors: MASANORI YAMAGUCHI, YUICHI KITA, TETSUYA MORI, KENJI KANBE, AKIHIRO TOMODA, ATSUSHI TAKAHASHI, WAKAKO ICHIKAWA
-
Patent number: 7745671Abstract: It is intended to provide a novel NAD+-independent myo-inositol 2-dehydrogenase which converts myo-inositol into scyllo-inosose in the absence of NAD+; a novel enzyme scyllo-inositol dehydrogenase which stereospecifically reduces scyllo-inosose into scyllo-inositol in the presence of NADH or NADPH; and a novel microorganism which belongs to the genus Acetobacter or Burkholderia and can convert myo-inositol into scyllo-inositol. By using these enzymes or the microorganism, scyllo-inositol is produced. Furthermore, scyllo-inositol is purified by adding boric acid and a metal salt to a liquid mixture containing scyllo-inositol and a neutral saccharide other than scyllo-inositol to form a scyllo-inositol/boric acid complex, separating the complex from the liquid mixture, dissolving the thus separated complex in an acid to give an acidic solution or an acidic suspension and then purifying scyllo-inositol from the acidic solution or the acidic suspension.Type: GrantFiled: October 14, 2004Date of Patent: June 29, 2010Assignee: Hokko Chemical Industry Co., Ltd.Inventors: Masanori Yamaguchi, Yuichi Kita, Tetsuya Mori, Kenji Kanbe, Akihiro Tomoda, Atsushi Takahashi, Wakako Ichikawa
-
Patent number: 7157268Abstract: Provided are novel processes for the efficient production of L-epi-2-inosose and epi-inositol which are useful either as various medicines or intermediates for the syntheses of various medicines. In the processes, inexpensive myo-inositol is used as a starting compound which is reacted with a gram-negative bacterium capable of converting myo-inositol into L-epi-2-inosose, and thereby producing L-epi-2-inosose by conversion of myo-inositol into L-epi-2-inosose. A biologically pure culture of Pseudomonas sp. AB 10215 strain is also provided which has a characteristic nature of being capable of converting myo-inositol into L-epi-2-inosose.Type: GrantFiled: May 25, 2004Date of Patent: January 2, 2007Assignees: Hokko Chemical Industry Co., Ltd., Zaidan Hojin Biseibutsu Kagaku Kenkyu KaiInventors: Atsushi Takahashi, Kenji Kanbe, Tetsuya Mori, Yuichi Kita, Tsuyoshi Tamamura, Tomio Takeuchi
-
Publication number: 20060240534Abstract: It is intended to provide a novel NAD+-independent myo-inositol 2-dehydrogenase which converts myo-inositol into scyllo-inosose in the absence of NAD+; a novel enzyme scyllo-inositol dehydrogenase which stereospecifically reduces scyllo-inosose into scyllo-inositol in the presence of NADH or NADPH; and a novel microorganism which belongs to the genus Acetobacter or Burkholderia and can convert myo-inositol into scyllo-inositol. By using these enzymes or the microorganism, scyllo-inositol is produced. Furthermore, scyllo-inositol is purified by adding boric acid and a metal salt to a liquid mixture containing scyllo-inositol and a neutral saccharide other than scyllo-inositol to form a scyllo-inositol/boric acid complex, separating the complex from the liquid mixture, dissolving the thus separated complex in an acid to give an acidic solution or an acidic suspension and then purifying scyllo-inositol from the acidic solution or the acidic suspension.Type: ApplicationFiled: October 14, 2004Publication date: October 26, 2006Inventors: Masanori Yamaguchi, Yuichi Kita, Tetsuya Mori, Kenji Kanbe, Akihiro Tomoda, Atsushi Takahashi, Wakako Ichikawa
-
Patent number: 6818430Abstract: Provided are novel processes for the efficient production of L-epi-2-inosose and epi-inositol which are useful either as various medicines or intermediates for the syntheses of various medicines. In the processes, there is used inexpensive myo-inositol as a starting compound. That is, there is now developed a new process which comprises reacting myo-inositol with a gram-negative bacterium capable of converting myo-inositol into L-epi-2-inosose, and thereby producing L-epi-2-inosose by conversion of myo-inositol into L-epi-2-inosose. Further, a novel process is provided, which comprises reacting the so produced L-epi-2-inosose with a reducing agent made of an alkali metal boron hydride or any other alkali metal hydride in an aqueous reaction medium, to produce epi-inositol and myo-inositol, and then isolating epi-inositol from the resulting reaction product composed of the epi-inositol and myo-inositol.Type: GrantFiled: February 12, 2002Date of Patent: November 16, 2004Assignees: Hokko Chemical Industry Co., Ltd., Zaidan Hojin Biseibutsu Kagaku Kenkyu KaiInventors: Atsushi Takahashi, Kenji Kanbe, Tetsuya Mori, Yuichi Kita, Tsuyoshi Tamamura, Tomio Takeuchi
-
Publication number: 20040214307Abstract: Provided are novel processes for the efficient production of L-epi-2-inosose and epi-inositol which are useful either as various medicines or intermediates for the syntheses of various medicines. In the processes, inexpensive myo-inositol is used as a starting compound which is reacted with a gram-negative bacterium capable of converting myo-inositol into L-epi-2-inosose, and thereby producing L-epi-2-inosose by conversion of myo-inositol into L-epi-2-inosose. A biologically pure culture of Pseudomonas sp. AB 10215 strain is also provided which has a characteristic nature of being capable of converting myo-inositol into L-epi-2-inosose.Type: ApplicationFiled: May 25, 2004Publication date: October 28, 2004Inventors: Atsushi Takahasi, Kenji Kanbe, Tetsuya Mori, Yuichi Kita, Tsuyoshi Tamamura, Tomio Takeuchi
-
Patent number: 5714643Abstract: An aqueous solution of kasugamycin or its salt is either mixed with a strongly acidic ion-exchange resin of the H.sup.+ -form in a reaction vessel, or is brought into contact with a strongly acidic ion-exchange resin of the H.sup.+ -form in a column containing said resin, followed by heating said aqueous solution and the resin under an atmospheric pressure or an elevated pressure, thereby to effect hydrolytic reaction of kasugamycin. By this reaction, an acidic reaction solution containing D-chiro-inositol is produced. This acidic reaction solution containing D-chiro-inositol is separated from the strongly acidic ion-exchange resin. Subsequently, D-chiro-inositol is recovered from the reaction solution. For this recovery, the acidic reaction solution is passed successively through a column of a strongly acidic ion-exchange resin of the H.sup.+ -form and through a column of a strongly basic ion exchange resin of the OH.sup.- -form, so that a neutral aqueous eluate containing D-chiro-inositol is obtained.Type: GrantFiled: February 9, 1996Date of Patent: February 3, 1998Assignees: Hokko Chemical Co., Ltd., Zaidan Hojin Biseibutsu Kagaku Kenkyu KaiInventors: Kiyoshi Sato, Makoto Yoshida, Kenji Kanbe, Kiyoshi Hirazawa, Tomio Takeuchi